Zai Lab picks up $30 mln Series C
Shanghai-based Zai Lab Limited, a biopharmaceutical company, has secured $30 million in Series C financing. OrbiMed led the round with participation from Vivo Capital, Cormorant and Rock Springs Capital. J.P. Morgan served as placement agent to Zai Lab on the transaction.
29 June 2017•1 min read
